Biologics in paediatric Crohn's disease

Gastroenterology Research and Practice

Volumn , Issue , 2011, Pages

  Gouldthorpe, Oliver ^a,b   Catto Smith, Anthony G ^b,c,d   Alex, George ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

BODY HEIGHT; CLINICAL EFFECTIVENESS; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FOLLOW UP; GROWTH DISORDER; HEALTH CARE ACCESS; HEPATITIS B; HUMAN; IMMUNIZATION; INFECTION; LOADING DRUG DOSE; LUPUS VULGARIS; LYMPHOMA; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEPSIS; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84855571922     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2011/287574     Document Type: Review

References (113)

1. Benchimol E. I., Fortinsky K. J., Gozdyra P., Van Den Heuvel M., Van Limbergen J., Griffiths A. M., Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends Inflammatory Bowel Diseases 2011 17 1 423 439
2. Phavichitr N., Cameron D. J. S., Catto-Smith A. G., Increasing incidence of Crohn's disease in Victorian children Journal of Gastroenterology and Hepatology 2003 18 3 329 332 (Pubitemid 36513163)
3. Loftus E. V. Jr., Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Gastroenterology 2004 126 6 1504 1517 (Pubitemid 38649869)
4. Bernklev T., Jahnsen J., Lygren I., Henriksen M., Vatn M., Moum B., Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms Inflammatory Bowel Diseases 2005 11 10 909 918 (Pubitemid 41428850)
5. Kappelman M. D., Porter C. Q., Galanko J. A., Rifas-Shiman S. L., Ollendorf D. A., Sandler R. S., Finkelstein J. A., Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease Inflammatory Bowel Diseases 2011 17 1 62 68
6. Kim S. C., Ferry G. D., Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations Gastroenterology 2004 126 6 1550 1560 (Pubitemid 38649872)
7. Sauer C. G., Kugathasan S., Pediatric inflammatory Bowel disease: highlighting pediatric differences in IBD Gastroenterology Clinics of North America 2009 38 4 611 628
8. Vernier-Massouille G., Balde M., Salleron J., Turck D., Dupas J. L., Mouterde O., Merle V., Salomez J. L., Branche J., Marti R., Lerebours.., Cortot A., Gower-Rousseau C., Colombel J. F., Natural history of pediatric Crohn's disease: a population-based cohort study Gastroenterology 2008 135 4 1106 1113
9. Van Limbergen J., Russell R. K., Drummond H. E., Aldhous M. C., Round N. K., Nimmo E. R., Smith L., Gillett P. M., McGrogan P., Weaver L. T., Bisset W. M., Mahdi G., Arnott I. D., Satsangi J., Wilson D. C., Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease Gastroenterology 2008 135 4 1114 1122
10. Paul T., Birnbaum A., Pal D. K., Pittman N., Ceballos C., LeLeiko N. S., Benkov K., Distinct phenotype of early childhood inflammatory bowel disease Journal of Clinical Gastroenterology 2006 40 7 583 586 (Pubitemid 44259761)
11. Polito J. M. II, Childs B., Mellits E. D., Tokayer A. Z., Harris M. L., Bayless T. M., Crohn's disease: influence of age at diagnosis on site and clinical type of disease Gastroenterology 1996 111 3 580 586 (Pubitemid 26293220)
12. Freeman H. J., Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence Canadian Journal of Gastroenterology 2004 18 11 661 665 (Pubitemid 39642505)
13. Kugathasan S., Cohen S., Searching for new clues in inflammatory bowel disease: tell tales from pediatric IBD natural history studies Gastroenterology 2008 135 4 1038 1041
14. Imielinski M., Baldassano R. N., Griffiths A., Russell R. K., Annese V., Dubinsky M., Kugathasan S., Bradfield J. P., Walters T. D., Sleiman P., Kim C. E., Muise A., Wang K., Glessner J. T., Saeed S., Zhang H., Frackelton E. C., Hou C., Flory J. H., Otieno G., Chiavacci R. M., Grundmeier R., Castro M., Latiano A., Dallapiccola B., Stempak J., Abrams D. J., Taylor K., McGovern D., Heyman M. B., Ferry G. D., Kirschner B., Lee J., Essers J., Grand R., Stephens M., Levine A., Piccoli D., Van Limbergen J., Cucchiara S., Monos D. S., Guthery S. L., Denson L., Wilson D. C., Grant S. F. A., Daly M., Silverberg M. S., Satsangi J., Hakonarson H., Common variants at five new loci associated with early-onset inflammatory bowel disease Nature Genetics 2009 41 12 1335 1340
15. Vermeire S., van Assche G., Rutgeerts P., Role of genetics in prediction of disease course and response to therapy World Journal of Gastroenterology 2010 16 21 2609 2615
16. Borrelli O., Cordischi L., Cirulli M., Paganelli M., Labalestra V., Uccini S., Russo P. M., Cucchiara S., Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial Clinical Gastroenterology and Hepatology 2006 4 6 744 753 (Pubitemid 43825808)
17. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F., A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease Gastroenterology 2000 119 4 895 902
18. Prantera C., Zannoni F., Scribano M. L., Berto E., Andreoli A., Kohn A., Luzi C., An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin American Journal of Gastroenterology 1996 91 2 328 332 (Pubitemid 26067343)
19. Cezard J. P., Munck A., Mouterde O., Morali A., Lenaerts C., Lachaux A., Turck D., Schmitz J., Maurage C., Girardet J. P., Belli D., Lamireau T., Sarles J., Chouraqui J. P., Descos B., Dabadi A., Meyer M., Olives J. P., Mary J. Y., Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial Gastroenterologie Clinique et Biologique 2009 33 1 31 40
20. Markowitz J., Early inflammatory bowel disease: different treatment response to specific or all medications? Digestive Diseases 2009 27 3 358 365
21. Tung J., Loftus E. V., Freese D. K., El-Youssef M., Zinsmeister A. R., Melton L. J., Harmsen W. S., Sandborn W. J., Faubion W. A., A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis Inflammatory Bowel Diseases 2006 12 12 1093 1100 (Pubitemid 44847465)
22. Goodhand J., Dawson R., Hefferon M., Tshuma N., Swanson G., Wahed M., Croft N. M., Lindsay J. O., Inflammatory bowel disease in young people: the case for transitional clinics Inflammatory Bowel Diseases 2010 16 6 947 952
23. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Singh R. R., TNF blockade in human diseases: mechanisms and future directions Clinical Immunology 2008 126 2 121 136
24. Knight D. M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., Scallon B., Moor M. A., Vilcek J., Daddona P., Ghrayeb J., Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Molecular Immunology 1993 30 16 1443 1453
25. Van Assche G., Vermeire S., Rutgeerts P., Infliximab therapy for patients with inflammatory bowel disease: 10 years on European Journal of Pharmacology 2009 623 1 S17 S25
26. Bousvaros A., Use of immunomodulators and biologic therapies in children with inflammatory bowel disease Expert Review of Clinical Immunology 2010 6 4 659 666
27. Markowitz J., Rosa J., Grancher K., Aiges H., Daum F., Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease Gastroenterology 1990 99 5 1347 1351 (Pubitemid 20381869)
28. Hanauer S. B., Crohn's disease: step up or top down therapy Bailliere's Best Practice and Research in Clinical Gastroenterology 2003 17 1 131 137
29. D'Haens G. R., Top-down therapy for IBD: rationale and requisite evidence Nature Reviews Gastroenterology and Hepatology 2010 7 2 86 92
30. Hyams J. S., Ferry G. D., Mandel F. S., Gryboski J. D., Kibort P. M., Kirschner B. S., Griffiths A. M., Katz A. J., Grand R. J., Boyle J. T., Michener W. M., Levy J. S., Lesser M. L., Development and validation of a pediatric Crohn's disease activity index Journal of Pediatric Gastroenterology and Nutrition 1991 12 4 439 447
31. Best W. R., Becktel J. M., Singleton J. W., Kern F., Development of a Crohn's disease activity index. National cooperative Crohn's disease study Gastroenterology 1976 70 3 439 444
32. Turner D., Griffiths A. M., Walters T. D., Seah T., Markowitz J., Pfefferkorn M., Keljo D., Otley A., Leleiko N. S., MacK D., Hyams J., Levine A., Appraisal of the pediatric crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties American Journal of Gastroenterology 2010 105 9 2085 2092
33. D'Haens G., Mucosal healing in pediatric Crohn's disease: the goal of medical treatment Inflammatory Bowel Diseases 2004 10 4 479 480 (Pubitemid 39029195)
34. Targan S. R., Hanauer S. B., van Deventer S. J. H., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's Disease The New England Journal of Medicine 1997 337 15 1029 35
35. Hanauer S. B., Feagan B. G., Lichtenstein G. R., Mayer L. F., Schreiber S., Colombel J. F., Rachmilewitz D., Wolf D. C., Olson A., Bao W., Rutgeerts P., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial The Lancet 2002 359 9317 1541 1549 (Pubitemid 34621118)
36. Sands B. E., Anderson F. H., Bernstein C. N., Chey W. Y., Feagan B. G., Fedorak R. N., Kamm M. A., Korzenik J. R., Lashner B. A., Onken J. E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D. C., Marsters P. A., Travers S. B., Blank M. A., Van Deventer S. J., Infliximab maintenance therapy for fistulizing Crohn's disease The New England Journal of Medicine 2004 350 9 876 885 (Pubitemid 38252535)
37. OECBM Levels of Evidence Working Group,. The Oxford 2011 Levels of Evidence, Oxford Centre for Evidence-Based Medicine, 2011
38. Baldassano R., Braegger C. P., Escher J. C., DeWoody K., Hendricks D. F., Keenan G. F., Winter H. S., Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease American Journal of Gastroenterology 2003 98 4 833 838 (Pubitemid 36576310)
39. Cezard J. P., Nouaili N., Talbotec C., Hugot J. P., Gobert J. G., Schmitz J., Mougenot J. F., Alberti C., Goulet O., A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease Journal of Pediatric Gastroenterology and Nutrition 2003 36 5 632 636 (Pubitemid 39274589)
40. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., Liu G., Travers S., Heuschkel R., Markowitz J., Cohen S., Winter H., Veereman-Wauters G., Ferry G., Baldassano R., Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children Gastroenterology 2007 132 3 863 873 (Pubitemid 46454266)
41. Colombel J. F., Sandborn W. J., Reinisch W., Mantzaris G. J., Kornbluth A., Rachmilewitz D., Lichtiger S., D'Haens G., Diamond R. H., Broussard D. L., Tang K. L., Van Der Woude C. J., Rutgeerts P., Infliximab, azathioprine, or combination therapy for Crohn's disease The New England Journal of Medicine 2010 362 15 1383 1395
42. Ruemmele F. M., Lachaux A., Cézard J. P., Morali A., Maurage C., Ginis J. L., Viola S., Goulet O., Lamireau T., Scaillon M., Breton A., Sarles J., Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy Inflammatory Bowel Diseases 2009 15 3 388 394
43. Harvey R. F., Bradshaw J. M., A simple index of Crohn's-disease activity The Lancet 1980 1 8167 514
44. Best W. R., Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index Inflammatory Bowel Diseases 2006 12 4 304 310
45. Hyams J. S., Lerer T., Griffiths A., Pfefferkorn M., Kugathasan S., Evans J., Otley A., Carvalho R., Mack D., Bousvaros A., Rosh J., Mamula P., Kay M., Crandall W., Oliva-Hemker M., Keljo D., LeLeiko N., Markowitz J., Long-term outcome of maintenance infliximab therapy in children with Crohn's disease Inflammatory Bowel Diseases 2009 15 6 816 822
46. Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P., Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clinical Gastroenterology and Hepatology 2004 2 7 542 553 (Pubitemid 38834038)
47. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cézard J. P., Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease Clinical Immunology 2006 118 1 11 19 (Pubitemid 43012041)
48. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P., Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 2007 56 9 1226 1231 (Pubitemid 47300423)
49. Mantzaris G. J., Viazis N., Petraki K., Papamichael K., Theodoropoulos I., Roussos A., Karakoidas C., Koilakou S., Raptis N., Smyrnidis A., Agalos G., Karamanolis D. G., A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab European Journal of Gastroenterology and Hepatology 2009 21 9 1042 1048
50. Kugathasan S., Saubermann L. J., Smith L., Kou D., Itoh J., Binion D. G., Levine A. D., Blumberg R. S., Fiocchi C., Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease Gut 2007 56 12 1696 1705 (Pubitemid 350206296)
51. Kim M. J., Lee J. S., Lee J. H., Kim J. Y., Choe Y. H., Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing top-down and step-up strategies Acta Paediatrica 2011 100 3 451 455
52. Dubinsky M. C., Mei L., Friedman M., Dhere T., Haritunians T., Hakonarson H., Kim C., Glessner J., Targan S. R., McGovern D. P., Taylor K. D., Rotter J. I., Genome Wide Association (GWA) predictors of anti-TNF therapeutic responsiveness in pediatric inflammatory bowel desease Inflammatory Bowel Diseases 2010 16 8 1357 1366
53. Hanauer S. B., Sandborn W. J., Rutgeerts P., Fedorak R. N., Lukas M., Macintosh D., Panaccione R., Wolf D., Pollack P., Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 2006 130 2 323 332 (Pubitemid 43202032)
54. Colombel J., Sandborn W. J., Rutgeerts P., Enns R., Hanauer S. B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J. D., Pollack P. F., Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 2007 132 1 52 65 (Pubitemid 46108762)
55. Sandborn W. J., Hanauer S. B., Rutgeerts P., Fedorak R. N., Lulcas M., MacIntosh D. G., Panaccione R., Wolf D., Kent J. D., Bittle B., Li J., Pollack P. F., Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 2007 56 9 1232 1239 (Pubitemid 47300424)
56. Feagan B. G., Panaccione R., Sandborn W. J., D'Haens G. R., Schreiber S., Rutgeerts P. J., Loftus E. V., Lomax K. G., Yu A. P., Wu E. Q., Chao J., Mulani P., Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study Gastroenterology 2008 135 5 1493 1499
57. Swoger J. M., Loftus E. V. Jr., Tremaine W. J., Faubion W. A., Pardi D. S., Kane S. V., Hanson K. A., Harmsen W. S., Zinsmeister A. R., Sandborn W. J., Adalimumab for Crohns disease in clinical practice at Mayo clinic: the first 118 patients Inflammatory Bowel Diseases 2010 16 11 1912 1921
58. Viola F., Civitelli F., Di Nardo G., Barbato M. B., Borrelli O., Oliva S., Conte F., Cucchiara S., Efficacy of adalimumab in moderate-to-severe pediatric crohn's disease American Journal of Gastroenterology 2009 104 10 2566 2571
59. Rosh J. R., Lerer T., Markowitz J., Goli S. R., Mamula P., Noe J. D., Pfefferkorn M. D., Kelleher K. T., Griffiths A. M., Kugathasan S., Keljo D., Oliva-Hemker M., Crandall W., Carvalho R. S., MacK D. R., Hyams J. S., Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric crohns disease American Journal of Gastroenterology 2009 104 12 3042 3049
60. Russell R. K., Wilson M. L., Loganathan S., Bourke B., Kiparissi F., Mahdi G., Torrente F., Rodrigues A., Davies I., Thomas A., Akobeng A. K., Fagbemi A., Hyer W., Spray C., Vaish S., Rogers P., McGrogan P., Heuschkel R. B., Ayub N., Fell J. M., Afzal N. A., Green M., Murphy M. S., Rao P., Shah N., Ho G. -T., Naik S., Wilson D. C., A british society of paediatric gastroenterology, hepatology and nutrition survey of the effectiveness and safety of Adalimumab in children with inflammatory bowel disease Alimentary Pharmacology and Therapeutics 2011 33 8 946 953
61. Rosenbach Y., Hartman C., Shapiro R., Hirsch A., Avitzur Y., Shamir R., Adalimumab treatment in children with refractory crohn's disease Digestive Diseases and Sciences 2010 55 3 747 753
62. Sandborn W. J., Feagan B. G., Stoinov S., Honiball P. J., Rutgeerts P., Mason D., Bloomfield R., Schreiber S., Certolizumab pegol for the treatment of Crohn's disease The New England Journal of Medicine 2007 357 3 228 238 (Pubitemid 47080387)
63. Schreiber S., Khaliq-Kareemi M., Lawrance I. C., Thomsen O.., Hanauer S. B., McColm J., Bloomfield R., Sandborn W. J., Maintenance therapy with certolizumab pegol for Crohn's disease The New England Journal of Medicine 2007 357 3 239 250 (Pubitemid 47080388)
64. Schreiber S., Lawrance I. C., Thomsen O.., Hanauer S. B., Bloomfield R., Sandborn W. J., Randomised clinical trial: certolizumab pegol for fistulas in Crohn's diseasesubgroup results from a placebo-controlled study Alimentary Pharmacology and Therapeutics 2011 33 2 185 193
65. Targan S. R., Feagan B. G., Fedorak R. N., Lashner B. A., Panaccione R., Present D. H., Spehlmann M. E., Rutgeerts P. J., Tulassay Z., Volfova M., Wolf D. C., Hernandez C., Bornstein J., Sandborn W. J., Natalizumab for the Treatment of Active Crohn's Disease: results of the ENCORE Trial Gastroenterology 2007 132 5 1672 1683 (Pubitemid 46695722)
66. Hyams J. S., Wilson D. C., Thomas A., Heuschkel R., Mitton S., Mitchell B., Daniels R., Libonati M. A., Zanker S., Kugathasan S., Natalizumab therapy for moderate to severe Crohn disease in adolescents Journal of Pediatric Gastroenterology and Nutrition 2007 44 2 185 191 (Pubitemid 46175070)
67. Motil K. J., Grand R. J., Davis-Kraft L., Ferlic L. L., Smith E. O., Growth failure in children with inflammatory bowel disease: a prospective study Gastroenterology 1993 105 3 681 691 (Pubitemid 23249475)
68. Sawczenko A., Sandhu B. K., Presenting features of inflammatory bowel disease in Great Britain and Ireland Archives of Disease in Childhood 2003 88 11 995 1000 (Pubitemid 37449406)
69. Sawczenko A., Ballinger A. B., Savage M. O., Sanderson I. R., Clinical features affecting final adult height in patients with pediatric-onset crohn's disease Pediatrics 2006 118 1 124 129 (Pubitemid 46071155)
70. Newby E. A., Sawczenko A., Thomas A. G., Wilson D., Interventions for growth failure in childhood Crohn's disease Cochrane Database of Systematic Reviews (Online) 2005 3, article CD003873
71. MacRae V. E., Wong S. C., Farquharson C., Ahmed S. F., Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases (review) International Journal of Molecular Medicine 2006 18 6 1011 1018
72. Wong S. C., Smyth A., McNeill E., Galloway P. J., Hassan K., McGrogan P., Ahmed S. F., The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation Clinical Endocrinology 2010 73 2 220 228
73. Difedele L. M., He J., Bonkowski E. L., Han X., Held M. A., Bohan A., Menon R. K., Denson L. A., Tumor necrosis factor blockade restores growth hormone signaling in murine colitis Gastroenterology 2005 128 5 1278 1291 (Pubitemid 40712179)
74. Ahmed T. A., Buzzelli M. D., Lang C. H., Capen J. B., Shumate M. L., Navaratnarajah M., Nagarajan M., Cooney R. N., Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes American Journal of Physiology 2007 292 6 G1793 G1803
75. MacRae V. E., Farquharson C., Ahmed S. F., The restricted potential for recovery of growth plate chondrogenesis and longitudinal bone growth following exposure to pro-inflammatory cytokines Journal of Endocrinology 2006 189 2 319 328
76. Griffiths A. M., Otley A. R., Hyams J., Quiros A. R., Grand R. J., Bousvaros A., Feagan B. G., Ferry G. R., A review of activity indices and end points for clinical trials in children with Crohn's disease Inflammatory Bowel Diseases 2005 11 2 185 196 (Pubitemid 40711224)
77. Walters T. D., Gilman A. R., Griffiths A. M., Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease Inflammatory Bowel Diseases 2007 13 4 424 430 (Pubitemid 46668247)
78. Malik S., Wong S., Bishop J., Hassan K., McGrogan P., Ahmed S., Russell R., Improvement in growth of children with crohn disease following anti-TNF- therapy can be independent of pubertal progress and glucocorticoid reduction Journal of Pediatric Gastroenterology and Nutrition 2011 52 1 31 37
79. Sinitsky D. M., Lemberg D. A., Leach S. T., Bohane T. D., Jackson R., Day A. S., Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease Journal of Gastroenterology and Hepatology 2010 25 4 810 816
80. Tuchman S., Thayu M., Shults J., Zemel B. S., Burnham J. M., Leonard M. B., Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease Journal of Pediatrics 2008 153 4 484 490
81. Dubner S. E., Shults J., Baldassano R. N., Zemel B. S., Thayu M., Burnham J. M., Herskovitz R. M., Howard K. M., Leonard M. B., Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease Gastroenterology 2009 136 1 123 130
82. Thayu M., Leonard M. B., Hyams J. S., Crandall W. V., Kugathasan S., Otley A. R., Olson A., Johanns J., Marano C. W., Heuschkel R. B., Veereman-Wauters G., Griffiths A. M., Baldassano R. N., Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study Clinical Gastroenterology and Hepatology 2008 6 12 1378 1384
83. Gilbert L., He X., Farmer P., Rubin J., Drissi H., Van Wijnen A. J., Lian J. B., Stein G. S., Nanes M. S., Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2 A) is inhibited by tumor necrosis factor- The Journal of Biological Chemistry 2002 277 4 2695 2701 (Pubitemid 34953297)
84. Radeff J. M., Nagy Z., Stern P. H., Involvement of PKC- in PTH, TNF-, and IL-1 effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption Experimental Cell Research 2001 268 2 179 188 (Pubitemid 32744649)
85. Crandall W. V., Mackner L. M., Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model Alimentary Pharmacology and Therapeutics 2003 17 1 75 84 (Pubitemid 36140437)
86. Puchner T. C., Kugathasan S., Kelly K. J., Binion D. G., Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction Inflammatory Bowel Diseases 2001 7 1 34 37
87. Duburque C., Lelong J., Iacob R., Seddik M., Desreumaux P., Fournier C., Wallaert B., Cortot A., Colombel J. F., Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions Alimentary Pharmacology and Therapeutics 2006 24 5 851 858
88. Lahdenne P., Wikstrm A. M., Aalto K., Kolho K. L., Prevention of acute adverse events related to infliximab infusions in pediatric patients Arthritis Care amp; Research 2010 62 6 785 790
89. Zella G. C., Weinblatt M. E., Winter H. S., Drug-induced lupus associated with infliximab and adalimumab in an adolescent with crohn disease Journal of Pediatric Gastroenterology and Nutrition 2009 49 3 355 358
90. Behm B. W., Bickston S. J., Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease Cochrane Database of Systematic Reviews 2008 1 CD006893
91. Toruner M., Loftus E. V. Jr., Harmsen W. S., Zinsmeister A. R., Orenstein R., Sandborn W. J., Colombel J. F., Egan L. J., Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease Gastroenterology 2008 134 4 929 936 (Pubitemid 351451967)
92. Mow W. S., Abreu-Martin M. T., Papadakis K. A., Pitchon H. E., Targan S. R., Vasiliauskas E. A., High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy Clinical Gastroenterology and Hepatology 2004 2 4 309 313 (Pubitemid 38447195)
93. Shale M. J., Seow C. H., Coffin C. S., Kaplan G. G., Panaccione R., Ghosh S., Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease Alimentary Pharmacology and Therapeutics 2010 31 1 20 34
94. Miehsler W., Novacek G., Wenzl H., Vogelsang H., Knoflach P., Kaser A., Dejaco C., Petritsch W., Kapitan M., Maier H., Graninger W., Tilg H., Reinisch W., A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease Journal of Crohn's and Colitis 2010 4 3 221 256
95. Arana A., Allen S., Burkowitz J., Fantoni V., Ghatnekar O., Rico M. T., Vanhaverbeke N., Wentworth C. E., Brosa M., Arellano F. M., Infliximab paediatric crohns disease educational plan: a European, cross-sectional, multicentre evaluation Drug Safety 2010 33 6 489 501
96. Sellam J., Hamdi H., Roy C., Baron G., Lemann M., Puéchal X., Breban M., Berenbaum F., Humbert M., Weldingh K., Salmon D., Ravaud P., Emilie D., Mariette X., Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy Annals of the Rheumatic Diseases 2007 66 12 1610 1615 (Pubitemid 350205449)
97. Salmon-Ceron D., Tubach F., Lortholary O., Chosidow O., Bretagne S., Nicolas N., Cuillerier E., Fautrel B., Michelet C., Morel J., Puéchal X., Wendling D., Lemann M., Ravaud P., Mariette X., Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry Annals of the Rheumatic Diseases 2011 70 4 616 623
98. Lawrance I. C., Radford-Smith G. L., Bampton P. A., Andrews J. M., Tan P. -K., Croft A., Gearry R. B., Florin T. H.J., Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience Journal of Gastroenterology and Hepatology 2010 25 11 1732 1738
99. Ferkolj I., How to improve the safety of biologic therapy in Crohn's disease Journal of Physiology and Pharmacology 2009 60 supplement 7 67 70
100. Cheent K., Nolan J., Shariq S., Kiho L., Pal A., Arnold J., Case Report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's Disease Journal of Crohn's and Colitis 2010 4 5 603 605
101. Hiremath G., Duffy L., Leibowitz I., Infliximab-induced psoriasis in children with inflammatory bowel disease Journal of Pediatric Gastroenterology and Nutrition 2011 52 2 230 232
102. Ko J. M., Gottlieb A. B., Kerbleski J. F., Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases Journal of Dermatological Treatment 2009 20 2 100 108
103. Laukoetter M. G., Mennigen R., Hannig C. M., Osada N., Rijcken E., Vowinkel T., Krieglstein C. F., Senninger N., Anthoni C., Bruewer M., Intestinal cancer risk in Crohn's disease: a meta-analysis Journal of Gastrointestinal Surgery 2011 15 4 576 583
104. Diak P., Siegel J., La Grenade L., Choi L., Lemery S., McMahon A., Tumor necrosis factor blockers and malignancy in children: forty-eight cases reported to the food and drug administration Arthritis and Rheumatism 2010 62 8 2517 2524
105. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W. J., Colombel J., Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clinical Gastroenterology and Hepatology 2008 6 6 644 653 (Pubitemid 351783447)
106. Siegel C. A., Marden S. M., Persing S. M., Larson R. J., Sands B. E., Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis Clinical Gastroenterology and Hepatology 2009 7 8 874 881
107. Lewis J. D., Bilker W. B., Brensinger C., Deren J. J., Vaughn D. J., Strom B. L., Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 2001 121 5 1080 1087 (Pubitemid 33022087)
108. Kotlyar D. S., Osterman M. T., Diamond R. H., Porter D., Blonski W. C., Wasik M., Sampat S., Mendizabal M., Lin M. V., Lichtenstein G. R., A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease Clinical Gastroenterology and Hepatology 2011 9 1 36 41
109. Kandiel A., Fraser A. G., Korelitz B. I., Brensinger C., Lewis J. D., Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine Gut 2005 54 8 1121 1125 (Pubitemid 41025906)
110. White M. K., Khalili K., Pathogenesis of progressive multifocal leukoencephalopathyrevisited Journal of Infectious Diseases 2011 203 5 578 586
111. Yousry T. A., Major E. O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E. W., Jger H. R., Clifford D. B., Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy The New England Journal of Medicine 2006 354 9 924 933
112. Biogen Idec., Tysabri Prescriber Information 2010 San Francisco, Calif, USA Elan Pharmaceuticals
113. Caldwell P. H., Murphy S. B., Butow P. N., Craig J. C., Clinical trials in children The Lancet 2004 364 9436 803 811 (Pubitemid 39165102)